Related Experiment Video
Updated: Feb 14, 2026
Analysis of DNA Double-strand Break DSB Repair in Mammalian Cells
Published on: September 8, 2010
DNA Double Strand Break Repair - Related Synthetic Lethality
Monika Toma1, Tomasz Skorski2, Tomasz Sliwinski1
1Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Abstract:
Cancer is a heterogeneous disease with a high degree of diversity between and within tumors. Our limited knowledge of their biology results in ineffective treatment. However, personalized approach may represent a milestone in the field of anticancer therapy. It can increase specificity of treatment against tumor initiating cancer stem cells (CSCs) and cancer progenitor cells (CPCs) with minimal effect on normal cells and tissues. Cancerous cells carry multiple genetic and epigenetic aberrations which may disrupt pathways essential for cell survival. Discovery of synthetic lethality has led a new hope of creating effective and personalized antitumor treatment. Synthetic lethality occurs when simultaneous inactivation of two genes or their products causes cell death whereas individual inactivation of either gene is not lethal. The effectiveness of numerous anti-tumor therapies depends on induction of DNA damage therefore tumor cells expressing abnormalities in genes whose products are crucial for DNA repair pathways are promising targets for synthetic lethality. Here, we discuss mechanistic aspects of synthetic lethality in the context of deficiencies in DNA double strand break repair pathways. In addition, we review clinical trials utilizing synthetic lethality interactions and discuss the mechanisms of resistance.
Insights
Synthetic lethality offers a personalized cancer treatment approach by targeting cancer stem cells (CSCs) and cancer progenitor cells (CPCs). This strategy exploits genetic vulnerabilities, particularly in DNA repair pathways, for effective antitumor therapy with minimal harm to normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer exhibits significant heterogeneity, complicating treatment efficacy.
- Personalized medicine, targeting cancer stem cells (CSCs) and cancer progenitor cells (CPCs), offers improved specificity and reduced toxicity.
- Genetic and epigenetic aberrations in cancer cells disrupt essential survival pathways.
Purpose of the Study:
- To explore the mechanistic basis of synthetic lethality in cancer therapy.
- To investigate synthetic lethality in the context of DNA double-strand break repair deficiencies.
- To review current clinical trials and resistance mechanisms associated with synthetic lethality.
Main Methods:
- Review of mechanistic aspects of synthetic lethality.
- Focus on deficiencies in DNA double-strand break repair pathways.
- Analysis of clinical trials involving synthetic lethality interactions.
Main Results:
- Synthetic lethality involves the simultaneous inactivation of two genes, leading to cell death.
- Tumor cells with defects in DNA repair pathways are promising targets for synthetic lethality.
- Understanding these interactions can lead to more effective and personalized anticancer treatments.
Conclusions:
- Synthetic lethality presents a novel strategy for personalized anticancer therapy.
- Exploiting DNA repair deficiencies via synthetic lethality can enhance treatment efficacy.
- Further research into synthetic lethality and resistance mechanisms is crucial for clinical advancement.
More Related Videos
Related Concept Videos
02:04Fixing Double-strand Breaks
02:04Fixing Double-strand Breaks
02:25Overview of DNA Repair
Chemically...
02:25Overview of DNA Repair
01:36Mismatch Repair
01:59Lagging Strand Synthesis
There are several major differences between synthesis of the leading strand and synthesis of the lagging strand. 1) Leading strand synthesis happens in the direction of replication fork opening, whereas lagging strand synthesis happens in the...